|Articles|November 17, 2022
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells (Nov 2022)
Author(s)Univercells Technologies
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How Biopharma Navigates the 2026 Economic Shift
2
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
3
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
4
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
5